공고 • Feb 10
Pharma Mar, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025 Pharma Mar, S.A. announced that they will report fiscal year 2024 results on Feb 28, 2025 공고 • Oct 22
Pharma Mar, S.A. to Report Q3, 2024 Results on Oct 29, 2024 Pharma Mar, S.A. announced that they will report Q3, 2024 results on Oct 29, 2024 공고 • Oct 16
Pharmamar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer PharmaMar announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor atezolizumab (Tecentriq®) compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage Small Cell Lung Cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. The combination of lurbinectedin and atezolizumab demonstrated a statistically significant improvement in the primary endpoints of overall survival (OS) and progression-free survival (PFS), as assessed by an independent review facility (IRF), compared to treatment with atezolizumab alone. The combination was generally well-tolerated. The preliminary safety data in the ongoing trial is consistent with the known safety profiles of lurbinectedin and atezolizumab with no new safety signals observed in the combination arm. Jazz and Roche plan to submit these data for presentation at a future medical meeting. PharmaMar will submit a marketing authorisation application (MAA) to the EMA in the first half of 2025 to request regulatory approval in the European Union (EU). Lurbinectedin is available for use in 16 territories around the world. 공고 • Jul 27
Pharma Mar, S.A. to Report First Half, 2024 Results on Jul 30, 2024 Pharma Mar, S.A. announced that they will report first half, 2024 results on Jul 30, 2024 공고 • Jun 05
Pharma Mar Presents Encouraging Results At ASCO for Small Cell Lung Cancer PharmaMar presented data from a Phase II trial evaluating PharmaMar's lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. PharmaMar has a unique technological platform: the sea. Since 1986, it has been researching the marine ecosystem to discover innovative therapeutic alternatives for serious diseases, such as cancer, for this purpose it has invested more than EUR 1 billion since its foundation. After reaching patients all over the world and changing the paradigm of sarcoma treatment, in addition to having three therapies commercially available, it is currently working to improve the lives of patients with Small Cell Lung Cancer, the most aggressive type of lung cancer. Regarding this disease, the results presented by the company at ASCO show that the combination of its drug for this pathology, Zepzelca® (lurbinectedin), in combination with irinotecan produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days). Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Zepzelca® (lurbinectedin) is a synthetic compound derived from the tunicate Ecteinascidia turbinata found by PharmaMar in the Caribbean Sea, the Gulf of Mexico and the Mediterranean Sea. It is approved in 16 territories around the world. It received FDA accelerated approval in 2020 and has become the standard of care for second-line treatment in the United States. Confirmatory trials are currently underway, which may eventually lead to approval in Europe as well. One of the confirmatory studies, LAGOON, consists of three arms, one of which is lurbinectedin with irinotecan. The results presented at ASCO reinforce the rationale for including this combination as an experimental arm with this type of patient in this ongoing pivotal trial. 공고 • Jun 02
Pharma Mar, S.A., Annual General Meeting, May 31, 2023 Pharma Mar, S.A., Annual General Meeting, May 31, 2023, at 11:30 Central European Standard Time. Location: The Auditorio Municipal Villa de Colmenar Viejo calle Molino de Viento, s/n, 28770 Colmenar Viejo Madrid Spain Agenda: To review and, as the case may be, approve the Annual Financial Statements and Management Reports of Pharma Mar, S.A. and of its Consolidated Group for the fiscal year ended December 31, 2022; to re-elect of the Statutory Auditors of the Company and its Consolidated Group; to consider Ratification, appointment and re-election of members of the Board of Directors; to consider Amendment of article 3 of Chapter I (Incorporation of the Company) of the Company's Bylaws; to authorize the Board of Directors, with express power of substitution, to buyback treasury stock, by the Company and/or by its subsidiary companies, under the terms provided by current legislation, with express power to proceed its transfer or amortization with reduction of the share capital number, leaving without effect, in the amount not used, the delegation agreed by the General Shareholders' Meeting of previous year; and to consider other matters. 
